Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V Agreement Appears Set Between FDA And Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

Final package expected to be published in late summer following clearance by the administration.
Advertisement

Related Content

PDUFA V Commitment Letter Front-Loads Guidance, Meeting Milestones
FDA's Un-(User Fee) Funded Priorities
What’s In A PDUFA Reauthorization? Maybe These Issues…
Personalized Medicine Needs Personalized Advocacy To Advance, PhRMA Says
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers
NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Topics

Advertisement
UsernamePublicRestriction

Register

PS072170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel